Description

Blood-based biomarkers for Alzheimer’s disease, which detect beta-amyloid and phosphorylated tau (pTau) proteinopathy, are rapidly advancing. The utility and convenience of an accurate blood test have clear implications for accelerating and improving clinical research and practice. Several candidate markers exist, including mass spectrometry and immunoassay-measured A?42 and A?40, their ratio, and phosphorylated tau at threonine 217 (pTau217), 181 (pTau181), and other phosphorylated sites. Additionally, non-specific markers of neurodegeneration and astrogliosis, such as neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), play a role.
Tau, a microtubule-associated protein crucial for neuronal stability, is a major neuropathological hallmark of Alzheimer’s disease (AD). Hyperphosphorylation of the tau protein is thought to lead to pathological tau spread and neuronal death. Recent research studies have demonstrated elevated plasma levels of p-Tau 217 in AD patients. Furthermore, these levels increase in the early stages of the AD continuum and correlate with amyloid-PET positivity. These findings suggest that p-Tau 217 may serve as a promising blood-based biomarker for AD research, drug development, diagnosis, disease monitoring, and patient care.
Interest has recently turned to pTau217, as cerebrospinal fluid levels increase early in autosomal dominant Alzheimer’s disease and better discriminate Alzheimer’s disease from non-Alzheimer’s subgroups of cognitively impaired adults compared to pTau181. In plasma, pTau217 accurately differentiates individuals with neuropathologically defined Alzheimer’s disease from other dementia cases. Moreover, in vivo plasma pTau217 levels correlate with ex vivo protein levels and spatial burden in post-mortem brain tissue. Next, plasma pTau217 levels discriminate diagnostic groups informed by amyloid PET. Among impaired (Alzheimer’s disease or mild cognitive impairment (MCI)) A?+ participants, pTau217 levels are elevated compared to cognitively unimpaired (CU) A?? participants, and plasma pTau217 and tau PET signal show moderate to high agreement. Serial plasma pTau217 levels also differentiate Alzheimer’s disease from non-Alzheimer’s MCI, remaining stable and non-elevated in A?? patients while increasing over time in A?+ patients. These findings underscore the potential of p-Tau 217 as a valuable blood-based biomarker for AD research, drug development, diagnosis, disease monitoring, and patient care.

Product Specification

Host: Rabbit
Antigen: Tau (phospho T231)
Synonyms: p-Tau181, phospho T181
Immunogen: Synthetic peptide
Accession: P10636
Clone Number: SDT-177-1 / SDT-177-17 / SDT-202-2
Antibody Type: Rabbit mAb IgG
Application: Sandwich ELISA
Predicted Reactivity: mouse
Purification: Protein A
Concentration: 2 mg/ml
Physical Appearance: Liquid
Storage Buffer: 1x PBS, pH 7.4, 0.03% Proclin 300
Stability & Storage: 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied.